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developed and validated for determination of two anti-diabetic drugs, nateglinide and metformin
hydrochloride in co-formulations. Study was performed on pre-coated silica gel HPTLC plates using
chloroform:ethyl acetate:acetic acid (4:6:0.1 v/v/v) as the mobile phase. A TLC scanner set at 216 nm
was used for direct evaluation of the chromatograms in the reﬂectance/absorbance mode. Method
was validated according to ICH guidelines. The correlation coefﬁcients of calibration curves were
found to be 0.996 and 0.995 in the concentration range of 200–2400 and 500–3000 ng band1 for
nateglinide and metformin, respectively. The method had an accuracy of 99.72% for nateglinide
and 100.08% for metformin hydrochloride. The method had the potential to determine these drugs
simultaneously from dosage forms without any interference of the tablets excipients. Nateglinide and
metformin hydrochloride were also subjected to acid, base, oxidation, wet, heat and photo-degrada-
tion studies. The degradation products obtained were well resolved from the pure drugs with signif-
icantly different Rf values. As the method could effectively separate the drugs from its degradation
products, it can be used for stability-indicating analysis.
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lsevier1. Introduction
Diabetes mellitus is difﬁcult to control with a single oral hypo-
glycaemic agent and the rate of mono therapy failure is high.
Hence combination therapy with complementary classes of
drugs that act on different aspects of glycemic control would
be expected to be an effective strategy for the control of diabetes.
Nateglinide (Fig. 1a) is an amino-acid derivative which lowers
the blood glucose levels and stimulates insulin secretion. Chem-
ically, it is formulated as ()-N-[(trans-4-isopropylcyclohexyl)
a)
CH3
CH3
O
NH
O
OH
b)
N
CH3
CH3
NH
N
NH2
NH2
ClH
Figure 1 Chemical structure of nateglinide (a) and metformin
hydrochloride (b).
222 A.B. Thomas et al.carbonyl-D-phenylalanine salt and is used in the treatment of
type two diabetes mellitus (USP, 2010). Metformin hydrochlo-
ride (Fig. 1b) is a biguanide hypoglycaemic agent used in the
treatment of non-insulin-dependent diabetes mellitus. It is effec-
tive in glycemic control and decreases the intestinal absorption
of glucose. It is chemically formulated ofN,N-dimethylimidodi-
carbonimidicdiamide hydrochloride (IP, 2010; BP, 2010). These
two drugs are formulated as a tablet in a combined formulation.
Validated assays have been reported for each drug individ-
ually. For analysis of nateglinide from human plasma, high
performance liquid chromatographic analysis with UV detec-
tion (Steffen et al., 2003), LC/MS (Varanasi et al., 2008), cou-
marin-type ﬂuorescent detection (Malli et al., 2007), and
HPTLC/TLC determination (Gumieniczek et al., 2009) was re-
ported. Spectrophotometric techniques have also been re-
ported for determination of nateglinide in bulk and tablet
dosage forms (Jain et al., 2009; Rastogi et al., 2009). High per-
formance liquid chromatography for metformin individually
in human plasma (Amini et al., 2005; Yuen and Peh, 1998;
Cheng and Chou, 2001) and in combination with other drugs
in plasma and pharmaceutical dosage form (O¨nal, 2009; Zhang
et al., 2007; Lakshmi et al., 2009), LC/MS analysis (Mistri
et al., 2007), UV spectrophotometric quantitation methods in
bulk and pharmaceutical formulation (Arayne et al., 2009)
and HPTLC methods (Ghassempour et al., 2006) have been
reported.
There are no reported assay methods that permit the simul-
taneous quantiﬁcation of nateglinide and metformin hydro-
chloride in combined dosage form. The aim of the present
work was to develop and validate a new simple, rapid, selec-
tive, cost effective and stability indicating HPTLC method
for simultaneous determination of nateglinide and metformin
hydrochloride in pharmaceutical formulation.2. Experimental
2.1. Materials
Analytical pure samples of nateglinide (C.C. Lab., Torrent
Pharmaceutical Ltd., Indrad, India) and metformin hydro-
chloride (USV Limited, Baddi, Himachal Pradesh, India) were
used in the study. The pharmaceutical dosage form used in this
study was Glinate-MF (Glenmark Pharmaceutical Limited,
Baddi, Himachal Pradesh, India) procured from the local mar-
ket and labelled to contain 60 mg of nateglinide and 500 mg of
metformin hydrochloride per tablet. The solvents and chemi-
cals used in the study were of AR grade (Research Lab.,
Nashik, Maharastra, India).2.2. Instrumentation
Microsyringe (Linomat syringe 659.004, Hamilton-Bonaduz
Schweiz, Camag, Switzerland), pre-coated silica gel 60 F-254
aluminium plates (10 · 10 cm, 250 lm thickness; Merck,
Germany), Linomat 5 applicator (Camag, Muttenz, Switzer-
land), twin trough chamber (20 · 10 cm; Camag, Muttenz,
Switzerland), saturation pad (Camag, Muttenz, Switzerland),
UV chamber (Camag, Muttenz, Switzerland), TLC scanner
III (Camag, Muttenz, Switzerland), winCATS version 1.4.0
software (Camag, Muttenz, Switzerland) were used in this
study. Microsoft excel was also used to treat data statistically.2.3. Preparation of standard solutions
Standard stock solutions were prepared by dissolving sepa-
rately 10 mg of nateglinide and metformin hydrochloride each
in 10 mL of methanol to obtain a concentration of 1000 lg mL
1. The standard stock solutions were suitably diluted metha-
nol to obtain the working standard solutions of both nategli-
nide and metformin hydrochloride.
2.4. Preparation of sample solutions
Twenty tablets (Glinate-MF, labelled to contain 60 mg of nate-
glinide and 500 mg of metformin hydrochloride per tablet,
Glenmark Pharmaceutical Limited, Baddi, Himachal Pradesh,
India) were weighed and crushed to ﬁne powder. An accurately
weighed powder sample equivalent to 100 mg of metformin
hydrochloride was weighed, transferred to a 100 mL volumet-
ric ﬂask and volume made up to about 70 mL with methanol.
The solution was sonicated for about 30 min, then diluted to
volume with the same solvent and ﬁltered through Whatman
ﬁlter paper No. 42. Working sample solutions were freshly pre-
pared by diluting suitable volumes of the stock sample solution
with methanol.
2.5. Optimized chromatographic conditions
Suitable volumes of standard and sample solutions (lL) were
applied to the HPTLC plates, 10 mm from the bottom and
10 mm from the side edges in the form of bands or streaks with
band length of 6 mm. The mobile phase consisting of chloro-
form:ethyl acetate:acetic acid (4:6:0.1 v/v/v) was used in each
chromatographic run. Ascending development technique was
carried out in twin trough chambers. The optimized chamber
saturation time for the mobile phase was 20 min at room tem-
perature (25 ± 2 C) that was assisted by saturation pads. The
distance covered by the solvent front was 8 cm, which took
about 15 min. The spots were scanned using the TLC scanner
3 in the reﬂectance/absorbancemode at 216 nmand all measure-
ments were operated by winCATS software. Concentrations of
the separated compounds were determined from the intensity of
reﬂected light and peak areas were used for evaluation.
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The tablet sample solutions were prepared as discussed above.
Suitable working sample solutions (2.5 lL) containing metfor-
min hydrochloride and nateglinide in the concentration ratio
of 1:8.33 (2500 ng:300 ng of metformin hydrochloride and nate-
glinide, respectively) were prepared, applied on HPTLC plates
and analysed under the optimized chromatographic conditions.
2.7. Method validation
The method was validated in compliance with ICH guidelines
(ICH, 1994, 1996). The following parameters were used for
validation of the developed method.
2.7.1. Linearity
Linear relationship between peak area and concentration of
the drugs was evaluated over the concentration range ex-
pressed in ng band1 by making ﬁve replicate measurements
in the concentrations range of 200–2400 ng band1 for nategli-
nide and 500–3000 ng band1 for metformin hydrochloride,
respectively.
2.7.2. Precision
Precision of the developed method was studied by performing
repeatability and intermediate precision studies. The sample
application and measurement of peak area was determined
by performing six replicate measurements of the same band
using a sample solution containing 2500 ng band1 of metfor-
min hydrochloride and 300 ng band1 of nateglinide each.
2.7.3. Recovery studies
Recovery studies were carried out by spiking three different
known amounts of the standard substances to the drug product
(standard addition method). Hence, 240, 300 and 360 ng band
1 of nateglinide and 2000, 2500 and 3000 ng band1 of metfor-
min hydrochloride were spiked to the dosage form that con-
tained 300 and 2500 ng band1 of nateglinide and metformin
hydrochloride, respectively, after sample dilution.Figure 2 UV spectra comparison of the spots of the standards (1) and
(M).2.7.4. Limit of detection (LOD) and limit of quantitation
(LOQ)
The limits of detection and quantiﬁcation of the developed
method were calculated from the standard deviation of the
y-intercepts and slope of the calibration curves of nateglinide
and metformin hydrochloride using the formulae as given
below.
Limits of Detection ¼ 3a=S
Limits of Quantification ¼ 10a=S
where a is the standard deviation of the y-intercepts and S is
the slope of the calibration curve.
2.7.5. Robustness
The effect of deliberate variations in method parameters like
the composition of the mobile phase, volume of the mobile
phase, time from spotting to development and time from devel-
opment to scanning were evaluated in this study. The effect of
these changes on both the Rf values and peak areas was eval-
uated by calculating the relative standard deviations (RSD) for
each parameter.
2.7.6. Speciﬁcity
Peak purity of both nateglinide and metformin hydrochloride
was assessed to evaluate the speciﬁcity of the method. The
sample and standard bands were scanned at three different lev-
els, i.e., peak start (S), peak apex (M), and peak end (E) posi-
tions. The speciﬁcity of the method was also determined by
performing forced degradation studies. Standard stock solu-
tions (1000 lg mL1) of nateglinide and metformin hydrochlo-
ride were employed in the study.
2.8. Stability studies
To evaluate the stability indicating properties of the developed
HPTLC method, forced degradation studies were carried out
in accordance to the ICH guidelines. The standard drugs were
subjected to acid, base, oxidation, wet heat, dry heat and
photo-degradation studies.dosage forms (2) for nateglinide (N) and metformin hydrochloride
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HCl (0.001 M, 5 mL) was added separately to 5 mL methano-
lic stock solutions of nateglinide and metformin hydrochloride
in 25 mL volumetric ﬂasks. The mixtures were reﬂuxed at
40 C for 30 min and the volume was made up with methanol
(200 lg mL1). The forced degradation was performed in the
dark to exclude the possible degradation effect of light. The
resulting solutions (12.5 lL, 2500 ng band1 for metformin
hydrochloride and 1.5 lL, 300 ng band1 for nateglinide) were
applied to TLC plates and the chromatograms were run as de-
scribed above.
2.8.2. Base-induced degradation study
For the base degradation study, NaOH (0.001 M, 5 mL) was
added separately to 5 mL methanolic stock solutions of nate-
glinide and metformin hydrochloride in a 25 mL volumetric
ﬂask. The mixtures were reﬂuxed at 40 C for 30 min and the
volume was made up with methanol (200 lg mL1). The sam-
ples were then applied and analysed as described in the acid in-
duced degradation study.
2.8.3. Hydrogen peroxide-induced (oxidation) degradation
study
H2O2 (1.5%, 5 mL) was added separately to 5 mL methanolic
stock solutions of nateglinide and metformin hydrochloride in
25 mL volumetric ﬂasks and the volume was made up with
methanol (200 lg mL1). The sample solutions were reﬂuxed
at 40 C for 30 min. The samples were then applied and ana-
lysed as described in acid induced degradation study.Table 1 Assay results of the pharmaceutical dosage form.
Component Amount present (mg per tablet)
Nateglinide 60
Metformin hydrochloride 500
Tablet used for analysis – Glinate-MF (Glenmark Pharmaceutical Limit
a Denotes average of six estimation.
Figure 3 Typical densitogra2.8.4. Wet degradation study
For wet heat degradation study, 5 mL stock solutions of each
drug were transferred to 25 mL volumetric ﬂasks separately.
To each 5 mL methanol was added and the samples were re-
ﬂuxed at 40 C for 30 min. The volume was made up with
methanol (200 lg mL1) and then applied and analysed under
the optimized chromatographic conditions.
2.8.5. Heat degradation study
For dry heat degradation study, the standard powder drugs
were placed in an oven at 50 C for 24 h. Appropriate dilutions
were prepared in methanol and then analyzed under the opti-
mized chromatographic conditions.
2.8.6. Photo-degradation study
For the photo-degradation study, the standard powder drugs
were exposed to UV light in a photo-stability chamber for
24 h. Appropriate dilutions were prepared inmethanol and then
analysed under the optimized chromatographic conditions.
3. Results and discussion
3.1. HPTLC method optimization
For the selection of appropriate mobile phase for the effective
separation of nateglinide and metformin hydrochloride, several
runs were made by using mobile phases containing solvents of
varying polarity, at different concentration levels. Different
mobile phase systems like toluene:methanol, chloroform:% Amount founda SD % RSDa
100.48 0.606 0.603
100.10 0.369 0.368
ed, Baddi, Himachal Pradesh, India).
m of blank mobile phase.
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form:ethyl acetate:acetic acid at different concentration levels
were tried. Among the different mobile phase combinations
employed, the mobile phase consisting of chloroform:ethyl ace-
tate:acetic acid in the ratio of 4:6:0.1 v/v/v gave the best resolu-
tion with sharp well deﬁned peaks withRf values of 0.80 ± 0.02
and 0.17 ± 0.02 for nateglinide and metformin hydrochloride,
respectively. The use of acetic acid was found to be necessary
for the elution of metformin from the plate due to the fact that
it is a weak basic drug, thereby interacting with the unreacted
silanol groups on silica stationary phases (Ghassempour
et al., 2006). However, increasing the ratio of acetic acid was
found to be deleterious and affected the peak shape of nategli-
nide. For the selection of analytical wavelength for the quanti-
ﬁcation of the drugs, the standard spots applied on silica gel
were scanned and their overlain spectra were obtained on the
HPTLC instrument. From the overlain spectra (Fig. 2), it
was observed that both nateglinide and metformin hydrochlo-Table 2 Summary of linear regression and validation data.
Parameters* Nateglinid
Linearity range 200–2400
Linear regression equation y= 119.3
Slope ± SD 119.3 ± 0
Intercept ± SD 51.01 ± 0
Correlation coeﬃcient (r2) 0.996
Limit of detection (LOD) 0.020
Limit of quantiﬁcation (LOQ) 0.060
Repeatability (RSD) 0.725
Intra-day (RSD) 0.710
Inter-day (RSD) 0.790
* Denotes average of six estimations.
Table 4 Robustness study for the developed method.
Parameters Drug
Mobile phase composition (±0.1 mL) Nateg
Metfo
Amount of mobile phase (±5%) Nateg
Metfo
Time from spotting to chromatography (±10 min) Nateg
Metfo
Time from chromatography to scanning (±10 min) Nateg
Metfo
* Denotes average of three estimations at each level.
Table 3 Recovery study of the method (using the standard additio
Drug Recovery level (%) Initial amount (ng b
Nateglinide 80 300
100 300
120 300
Metformin hydrochloride 80 2500
100 2500
120 2500
* Denotes average of three estimations at each level of recovery.ride exhibited strong absorbance at about 216 nmwhich was se-
lected as the analytical wavelength for further analysis. The
densitogram of the blank mobile phase (Fig. 3) also showed
no peak conﬁrming the purity of the standard peaks obtained
using the proposed mobile phase.3.2. Analysis of marketed formulation
The marketed formulation, Glinate-MF was analysed using
the developed method. The chromatogram of tablet sample
showed only two peaks at Rf value of 0.80 and 0.17 for nate-
glinide and metformin hydrochloride, respectively, indicating
that there is no interference of the excipients present in the tab-
let formulation. The content of nateglinide and metformin
hydrochloride was calculated by comparing peak areas of sam-
ple with that of the standard (Table 1). The densitogram of
tablet formulation is shown in Fig. 4.e Metformin hydrochloride
ng band1 500–3000 ng band1
x+ 51.01 y= 174.0x+ 2191
.263 174.0 ± 0.524
.713 2191 ± 1.329
0.995
0.022
0.066
0.730
0.361
0.837
% SD* % RSD*
linide 0.297 0.296
rmin hydrochloride 0.543 0.543
linide 0.984 0.982
rmin hydrochloride 0.982 0.741
linide 0.539 0.534
rmin hydrochloride 0.951 0.947
linide 0.654 0.656
rmin hydrochloride 0.493 0.490
n method) for nateglinide and metformin hydrochloride.
and1) Amount added (ng band1) % Recovery* % RSD*
240 98.83 0.550
300 100.33 0.667
360 100 0.835
2000 100.37 0.276
2500 99.92 0.639
3000 99.95 0.420
Figure 4 Typical densitogram of nateglinide (1) and metformin hydrochloride (2) in pharmaceutical dosage form.
Figure 5 Typical densitogram of nateglinide, metformin hydrochloride and degradation products in the acid degradation study.
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3.3.1. Linearity
Peak areas were found to have better linear relationship with
the concentration than the peak heights. For nateglinide, ther2 was found to be 0.996, and for metformin hydrochloride
the r2 was 0.995. Calibration graphs were constructed in
the concentration range of 200–2400 ng band1 for nateglinide
and 500–3000 ng band1 for metformin hydrochloride. The
correlation coefﬁcients, y-intercepts and slopes of the regres-
Stability-indicating HPTLC method for simultaneousdetermination of nateglinide 227sion lines of the two drugs were calculated and are presented in
Table 2.
3.3.2. Precision
Repeatability and intermediate precision of the developed
method were expressed in terms of relative standard deviation
(RSD) of the peak area. The results showed that the repeat-
ability, intra- and inter-day variation of the results at concen-
tration of 300 ng band1 for nateglinide and 2500 ng band1
for metformin hydrochloride were within the acceptable range.
The coefﬁcients of variation for both the inter-day and intra-
day precision of the method was found to be less than 1%
for both drugs (Table 2).Figure 6 Typical densitogram of nateglinide, metformin hydroc
Table 5 Stability studies for the developed method.
Degradation condition Number of degradation produ
Acid 4 (0.03, 0.13, 0.87, 0.90)
Base 3 (0.06, 0.72, 0.92)
Oxidative 4 (0.04, 0.30, 0.59, 0.69)
Wet 2 (0.05, 0.84)
Heat 3 (0.16, 0.68, 0.90)
Photo 4 (0.05, 0.46, 0.64, 0.69)3.3.3. Accuracy/recovery studies
The recovery studies were carried out at 80%, 100% and 120%
of the test concentration as per ICH guidelines. The percentage
recovery of nateglinide and metformin hydrochloride at all the
three levels was found to be satisfactory (Table 3). For nategli-
nide, the % recovery was found between 98.83% and 100.33%
and for metformin hydrochloride between 99.92% and
100.37%, respectively.3.3.4. Limit of detection (LOD) and limit of quantitation
(LOQ)
The limits of detection and quantitation were found to be
0.020 and 0.060 ng band1 for nateglinide and 0.022 andhloride and degradation products in base degradation study.
cts (Rf values) Area of degradation product (%)
8.50, 2.88, 13.06, 7.09
5.94, 6.15, 15.29
7.86, 3.05, 11.46, 6.41
7.74, 17.45
4.47, 8.71, 12.09
4.37, 0.73, 8.05, 12.51
Figure 7 Typical densitogram of nateglinide, metformin hydrochloride and degradation products in oxidative degradation study.
228 A.B. Thomas et al.0.066 ng band1 for metformin hydrochloride, respectively,
indicating the sensitivity of the developed method.
3.3.5. Robustness of the method
The robustness of the method evaluated by assessing the effect
of variations in method parameters on peak areas showed low
RSD values (less than 1.0%) indicating robustness of the
method (Table 4).
3.3.6. Speciﬁcity
The peak purity test of nateglinide and metformin hydrochlo-
ride spots were assessed by comparing their respective spectra
at peak start, peak apex and peak end positions of the spot and
their spectra were overlaid to assess spectral matching.
3.4. Stability studies
The results of the forced degradation study of nateglinide and
metformin hydrochloride using chloroform:ethyl acetate:acetic
acid [4:6:0.1 (v/v/v)] as the mobile phase system are summa-
rized in Table 5.
3.4.1. Acid induced degradation study
Nateglinide and metformin hydrochloride, both were found to
undergo acid degradation very rapidly. The reaction in
0.001 M HCl at 40 C under reﬂux for 30 min showed exten-sive degradation for nateglinide with additional peaks at Rf
values of 0.87, 0.90 (about 13.06, 7.09% degradation), respec-
tively. For metformin hydrochloride, additional peaks were
observed with Rf values 0.03, 0.13 (about 8.50, 2.88% degrada-
tion), respectively (Fig. 5).3.4.2. Base induced degradation study
In base induced degradation study, nateglinide and metformin
hydrochloride showed additional peaks at Rf values 0.72, 0.92
(about 6.15, 15.29% degradation) and 0.06 (about 5.94% deg-
radation), respectively (Fig. 6).3.4.3. Oxidative induced degradation study
In the oxidative degradation study, it was found that both
nateglinide and metformin hydrochloride were extremely liable
to degradation. Nateglinide exhibited degradation peaks at Rf
values 0.59, 0.69 (about 11.46, 6.41% degradation), respec-
tively, and for metformin hydrochloride at Rf values 0.04,
0.30 (around 7.86, 3.05% degradation), respectively. The den-
sitogram for the oxidative degradation study is shown in
(Fig. 7).
3.4.4. Wet degradation study
The wet degradation studies suggested that both nateglinide
and metformin hydrochloride were labile to wet degradation
Figure 8 Typical densitogram of nateglinide, metformin hydrochloride and degradation products in wet degradation study.
Figure 9 Typical densitogram of nateglinide, metformin hydrochloride and degradation products in heat degradation study.
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17.45% degradation) and 0.05 (about 7.74% degradation),
respectively (Fig. 8).3.4.5. Heat degradation study
In the heat degradation study, nateglinide and metformin
hydrochloride showed additional peaks at Rf value at 0.68,
Figure 10 Typical densitogram of nateglinide, metformin hydrochloride and degradation products in photo-degradation study.
230 A.B. Thomas et al.0.90 (about 8.71, 7.09% degradation) and 0.16 (about 4.47%
degradation), respectively (Fig. 9).
3.4.6. Photo-degradation study
Nateglinide and metformin hydrochloride both showed addi-
tional peaks at Rf value 0.64, 0.69 (about 8.05, 12.51% degra-
dation) and 0.05, 0.46 (about 4.37, 0.73% degradation),
respectively, in the photo-degradation study (Fig. 10).
4. Conclusion
A combination of nateglinide and metformin hydrochloride is
currently available for the treatment of diabetes mellitus. As
there are no reported methods for their simultaneous estima-
tion, a stability indicating high performance thin layer chroma-
tography (HPTLC) method was developed and validated for
the determination of nateglinide and metformin hydrochloride
in co-formulations on pre-coated silica gel HPTLC plates
using chloroform:ethyl acetate:acetic acid (4:6:0.1 v/v/v) as
the mobile phase with densitometric detection at 216 nm.
The developed method was found to be simple, rapid, selective,
sensitive and suitable for simultaneous determination of nate-
glinide and metformin hydrochloride. The HPTLC method of-
fers several advantages over liquid chromatographic methods
such as the possibility of simultaneous analysis of sample
and standard on the same plate, short system equilibrium time,
multiple/repeated scanning of chromatograms, higher mobile
phase pH, large sample capacity, short run time, minimumsolution consumption and no prior treatment for solvents like
ﬁltration and degassing. The stability indicating properties
established following the recommendations of ICH guidelines
also indicated that the drugs could be evaluated in presence
of their degradation products and thereby can be employed
for the simultaneous estimation of nateglinide and metformin
hydrochloride and their degradation products in stability sam-
ples in the industry.Acknowledgements
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